Hanmi R&D becomes stronger through cooperation with partners.

Despite efficient weight loss, incretin therapy results in significant lean mass loss and impaired weight loss quality (WLQ). So, the development of novel therapy for WLQ improvement is of great interest in recent obesity market. To achieve this ultimate goal, Hanmi initiates LA-UCN2 project. HM17321 is a novel obesity drug discovered by combining Hanmi's scientific expertise with the modern AI and structural modeling technologies, and is a corticotropin-releasing factor 2 (CRF2) receptor selective urocortin-2 (UCN2) analog with a long-acting technology.

In nonclinical studies, HM17321 has demonstrated significant weight, fat mass reduction and lean mass increase in obese animal model, confirming its potential to improve a variety of metabolic conditions, including cardiovascular disease (CVD). By providing high quality obesity management and additional metabolic benefits, HM17321 is poised to be a game-changer in the rapidly growing obesity market.